Amy E. Tapper

Corporate Officer/Principal at IMAGO BIOSCIENCES, INC.

53 year

Health Technology

Consumer Services

Profile

Amy E.
Tapper is a professional with a doctorate degree from Boston University and an undergraduate degree from Boston College.
She is currently the Senior VP-Chemistry, Manufacturing & Controls at Imago BioSciences, Inc. She was previously the Senior Vice President at FerroKin BioSciences, Inc. from 2008 to 2012.

Amy E. Tapper active positions

Companies	Position	Start
IMAGO BIOSCIENCES, INC.	Corporate Officer/Principal	2012-09-30

All active positions of Amy E. Tapper

Former positions of Amy E. Tapper

Companies	Position	End
FerroKin BioSciences, Inc. FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA.	Corporate Officer/Principal	2011-12-31

See the detail of Amy E. Tapper's experience

Training of Amy E. Tapper

Boston University	Doctorate Degree
Boston College	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Amy E. Tapper's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
FerroKin BioSciences, Inc. FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA.	Health Technology
Imago BioSciences, Inc. Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA.	Health Technology